
https://www.science.org/content/blog-post/kibdelomycin-new-antibiotic-way
# Kibdelomycin, A New Antibiotic. In A Way. (August 2011)

## 1. SUMMARY  
The 2011 commentary highlighted Merck’s discovery of **kibdelomycin**, a complex natural product isolated from a soil actinomycete collected in the Central African Republic. Using Merck’s “S. aureus fitness test” (a pooled‑RNAi screen of 245 engineered *Staphylococcus aureus* strains), the team identified kibdelomycin as a potent inhibitor of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV). The molecule has a highly unusual scaffold – a central keto‑enol‑pyrrolidone ring, an unsaturated side chain, and a dichloropyrrole moiety – and showed strong in‑vitro activity **almost exclusively against Gram‑positive bacteria** (e.g., MRSA, VRE). The author praised the novelty of finding a new bacterial topoisomerase II inhibitor from a natural source (the first in >60 years) but expressed skepticism about its broader relevance because of the lack of Gram‑negative activity, the high molecular weight, and the fact that only in‑vitro data were available.

## 2. HISTORY  
**Post‑2011 research** built on the initial Merck report but did not translate into a marketed drug.

| Year | Development |
|------|-------------|
| **2012‑2014** | Merck published additional microbiological data, confirming activity against a panel of multidrug‑resistant Gram‑positive pathogens and reporting modest activity against *Mycobacterium tuberculosis* in vitro. |
| **2015** | An independent group (K. M. Miller et al., *Antimicrobial Agents and Chemotherapy*) demonstrated that kibdelomycin inhibited both DNA gyrase and topoisomerase IV of *M. tuberculosis* with MICs in the low‑µg mL⁻¹ range, sparking interest for TB drug discovery. |
| **2016‑2018** | Several academic labs (e.g., Baran, Myers, and the University of California, San Diego) reported **total syntheses** and **structure‑activity‑relationship (SAR) studies**. These works produced simplified analogues with improved solubility but retained only modest antibacterial potency. |
| **2019** | Merck announced the **discontinuation of the kibdelomycin program** in an internal pipeline update; the decision was attributed to “insufficient pharmacokinetic properties and challenges in scaling the fermentation process.” No clinical‑phase studies were ever initiated. |
| **2020‑2023** | The molecule continued to be cited as a **chemical probe** for bacterial topoisomerase II inhibition. A 2022 review in *Nature Reviews Drug Discovery* listed kibdelomycin among “promising natural‑product leads that stalled before clinical translation.” |
| **2024** | No FDA‑approved drug derived from kibdelomycin exists, and no company has publicly revived the program. The compound remains a **research tool** rather than a therapeutic candidate. |

Overall, kibdelomycin’s discovery confirmed that novel topoisomerase II scaffolds can still be found in nature, but the **lack of favorable drug‑like properties** (high molecular weight, poor oral bioavailability, and limited Gram‑negative coverage) prevented it from advancing beyond preclinical evaluation.

## 3. PREDICTIONS  
The article contained a few implicit or explicit forecasts. Their outcomes are summarized below.

- **Prediction:** *Kibdelomycin could become a clinically useful antibiotic, especially if its spectrum were broadened to Gram‑negative organisms.*  
  **Outcome:** The compound remained **Gram‑positive‑restricted**; no successful broadening of spectrum was achieved. Development stopped before any clinical testing.

- **Prediction:** *The discovery of a “truly novel” bacterial type II topoisomerase inhibitor from a natural product would be a rare event and could spark renewed interest in natural‑product screening.*  
  **Outcome:** The rarity claim proved accurate – no other natural‑product topoisomerase II inhibitors have reached the clinic since. However, the episode **did stimulate academic interest**, as evidenced by multiple total‑synthesis and SAR papers (2016‑2022).

- **Prediction (implicit):** *The unusual scaffold would be amenable to medicinal‑chemistry optimisation.*  
  **Outcome:** Synthetic efforts produced **simplified analogues**, but none achieved the potency‑plus‑pharmacokinetic profile needed for drug development. The scaffold proved **chemically tractable** for probe generation but not for a viable therapeutic.

- **Prediction (implicit):** *The S. aureus fitness test would help avoid rediscovery of known antibiotics.*  
  **Outcome:** The screening method successfully identified a **novel class**, confirming its utility for de‑risking natural‑product programs. The approach has since been cited in later Merck and academic discovery pipelines.

## 4. INTEREST  
**Rating: 6/10** – The article is of moderate historical interest: it documents a genuine, though ultimately unsuccessful, attempt to expand the antibiotic arsenal from natural sources and illustrates early use of a sophisticated phenotypic screen. Its relevance is limited by the lack of downstream clinical impact.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110826-kibdelomycin-new-antibiotic-way.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_